# Core-001

> **NIH NIH U19** · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2023 · $420,195

## Abstract

Although airway remodeling is well established to be present in asthma, the specific immune and 
inflammatory pathways leading to airway remodeling in human asthmatics are incompletely understood. 
“Severe Asthma Core B” will advance our understanding of the pathogenesis of airway remodeling in severe 
asthma by providing each of the project access to well characterized human lung bronchial brush, bronchial 
biopsy, bronchoalveolar lavage, and sputum specimens from severe asthma subjects (with varying levels 
of remodeling) and control subjects (mild asthma; non-asthma). This will allow individual Projects 1-3 to 
investigate whether the immune, inflammatory, and remodeling molecule/pathway they are studying is more 
highly expressed in severe asthma compared to control subjects, is more highly expressed in severe asthma 
compared to mild asthma, is more highly expressed in asthmatics with higher levels of remodeling, is 
expressed at levels that differ in lung airway anatomical compartments (i.e. proximal airway vs distal airway), 
and whether differences in expression levels are detectable in sputum to potentially use as a future 
biomarker of remodeling. Core B will also be a resource to provide well-characterized human severe asthma 
and control lung structural cells (epithelium, airway smooth muscle, fibroblast) and immune cells (tissueresident memory T cells or TRM) for study in each Project. Finally, Core B will allow investigators in each
project to utilize a novel ex vivo human lung airway bronchodilation, bronchoconstriction, and airway 
remodeling assay to determine whether the pathway/cell type they are studying influences bronchodilation, 
bronchoconstriction, or airway remodeling in human lung airways from asthma compared to controls. 
Overall, the provision of these human lung and sputum specimens from severe asthma and control subjects 
will allow the individual projects to determine whether the defined inflammatory and remodeling pathways 
they are investigating are different in asthmatics with differing levels of severity, or differing levels of 
remodeling, as compared to control subjects.

## Key facts

- **NIH application ID:** 10869417
- **Project number:** 5U19AI070535-18
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN DIEGO
- **Principal Investigator:** DAVID H BROIDE
- **Activity code:** U19 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $420,195
- **Award type:** 5
- **Project period:** 2006-07-01 → 2026-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10869417

## Citation

> US National Institutes of Health, RePORTER application 10869417, Core-001 (5U19AI070535-18). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10869417. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*